Tech Company Financing Transactions

Zentalis Pharmaceuticals Funding Round

Zentalis Pharmaceuticals secured a $85 million Series C financing round on 12/11/2019. Investors included Eventide Asset Management, Farallon Capital Management and Matrix Capital Management.

Transaction Overview

Announced On
12/11/2019
Transaction Type
Venture Equity
Amount
$85,000,000
Round
Series C
Proceeds Purpose
The proceeds from the Series C financing will be used to advance the Company's lead clinical candidates towards pivotal trials and to broaden the scope of Zentalis' ongoing clinical programs.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
530 Seventh Ave. 2201
New York, NY 10018
USA
Email Address
Overview
At Zentalis (Nasdaq: ZNTL), we are developing clinically differentiated therapeutics targeting fundamental cancer pathways that have the potential to address major unmet medical needs for patients with cancer. We have successfully advanced three compounds into the clinic in the Company's first five years, all internally developed using the deep chemistry capabilities of our integrated discovery engine.
Profile
Zentalis Pharmaceuticals LinkedIn Company Profile
Social Media
Zentalis Pharmaceuticals Company Twitter Account
Company News
Zentalis Pharmaceuticals News
Facebook
Zentalis Pharmaceuticals on Facebook
YouTube
Zentalis Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Anthony Sun
  Anthony Sun LinkedIn Profile  Anthony Sun Twitter Account  Anthony Sun News  Anthony Sun on Facebook
Chief Financial Officer
Melissa Epperly
  Melissa Epperly LinkedIn Profile  Melissa Epperly Twitter Account  Melissa Epperly News  Melissa Epperly on Facebook
Chief Medical Officer
Robert Winkler
  Robert Winkler LinkedIn Profile  Robert Winkler Twitter Account  Robert Winkler News  Robert Winkler on Facebook
Chief Operating Officer
Kevin Bunker
  Kevin Bunker LinkedIn Profile  Kevin Bunker Twitter Account  Kevin Bunker News  Kevin Bunker on Facebook
Vice President
Peter Huang
  Peter Huang LinkedIn Profile  Peter Huang Twitter Account  Peter Huang News  Peter Huang on Facebook
VP - Bus. Development
Lawrence Cripe
  Lawrence Cripe LinkedIn Profile  Lawrence Cripe Twitter Account  Lawrence Cripe News  Lawrence Cripe on Facebook
VP - General Counsel
Kimberley Overs
  Kimberley Overs LinkedIn Profile  Kimberley Overs Twitter Account  Kimberley Overs News  Kimberley Overs on Facebook
VP - Operations
Orna Bornstein
  Orna Bornstein LinkedIn Profile  Orna Bornstein Twitter Account  Orna Bornstein News  Orna Bornstein on Facebook
VP - R & D
Ahmed Samatar
  Ahmed Samatar LinkedIn Profile  Ahmed Samatar Twitter Account  Ahmed Samatar News  Ahmed Samatar on Facebook
VP - Regulatory Affairs
Meena Rao
  Meena Rao LinkedIn Profile  Meena Rao Twitter Account  Meena Rao News  Meena Rao on Facebook


 

 

Browse more venture capital transactions:

Prev: 12/11/2019: HypeLabs venture capital transaction
Next: 12/11/2019: Imply venture capital transaction

 

Share this article

 


News on VC Transactions

We report on every notable VC transaction. All VC database entries on this site are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary